Scienture Says US FDA Approves Oral Liquid Formulation of Hypertension Drug Losartan

MT Newswires Live2025-03-18

Scienture (SCNX) said Tuesday the US Food and Drug Administration approved its new drug application for Arbli, an oral suspension formulation of hypertension drug losartan potassium.

The company said Arbli is indicated for hypertension in patients older than 6 years old, stroke risk reduction in patients with hypertension and left ventricular hypertrophy, and diabetic nephropathy in certain patients with type 2 diabetes.

The company also said the product has two patents and is expected to be listed in the FDA's Orange Book.

Scienture said it plans to launch Arbli in the US in Q3.

Shares of the company were up more than 24% in recent Tuesday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2520671951?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-18 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520671951","market":"sg","top_or_hot":-1,"title":"Scienture Says US FDA Approves Oral Liquid Formulation of Hypertension Drug Losartan","media":"MT Newswires Live","content":"<html><body><p> Scienture (SCNX) said Tuesday the US Food and Drug Administration approved its new drug application for Arbli, an oral suspension formulation of hypertension drug losartan potassium.</p><p>The company said Arbli is indicated for hypertension in patients older than 6 years old, stroke risk reduction in patients with hypertension and left ventricular hypertrophy, and diabetic nephropathy in certain patients with type 2 diabetes.</p><p>The company also said the product has two patents and is expected to be listed in the FDA's <a href=\"https://laohu8.com/S/FNCTF\">Orange</a> Book.</p><p>Scienture said it plans to launch Arbli in the US in Q3.</p><p>Shares of the company were up more than 24% in recent Tuesday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scienture Says US FDA Approves Oral Liquid Formulation of Hypertension Drug Losartan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScienture Says US FDA Approves Oral Liquid Formulation of Hypertension Drug Losartan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-18 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Scienture (SCNX) said Tuesday the US Food and Drug Administration approved its new drug application for Arbli, an oral suspension formulation of hypertension drug losartan potassium.</p><p>The company said Arbli is indicated for hypertension in patients older than 6 years old, stroke risk reduction in patients with hypertension and left ventricular hypertrophy, and diabetic nephropathy in certain patients with type 2 diabetes.</p><p>The company also said the product has two patents and is expected to be listed in the FDA's <a href=\"https://laohu8.com/S/FNCTF\">Orange</a> Book.</p><p>Scienture said it plans to launch Arbli in the US in Q3.</p><p>Shares of the company were up more than 24% in recent Tuesday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4167","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2520671951","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520671951","pubTimestamp":1742303008,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Scienture  said Tuesday the US Food and Drug Administration approved its new drug application for Arbli, an oral suspension formulation of hypertension drug losartan potassium.The company said Arbli is indicated for hypertension in patients older than 6 years old, stroke risk reduction in patients with hypertension and left ventricular hypertrophy, and diabetic nephropathy in certain patients with type 2 diabetes.The company also said the product has two patents and is expected to be listed in the FDA's Orange Book.Scienture said it plans to launch Arbli in the US in Q3.Shares of the company were up more than 24% in recent Tuesday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4167":"医疗保健技术","SCNX":"Scienture Holdings, Inc."},"translate_title":"Scienture称美国FDA批准高血压药物氯沙坦口服液制剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SCNX":0.9},"content_text":"Scienture (SCNX) said Tuesday the US Food and Drug Administration approved its new drug application for Arbli, an oral suspension formulation of hypertension drug losartan potassium.The company said Arbli is indicated for hypertension in patients older than 6 years old, stroke risk reduction in patients with hypertension and left ventricular hypertrophy, and diabetic nephropathy in certain patients with type 2 diabetes.The company also said the product has two patents and is expected to be listed in the FDA's Orange Book.Scienture said it plans to launch Arbli in the US in Q3.Shares of the company were up more than 24% in recent Tuesday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2520671951","isCrawlerRequest":true}